Harmony Biosciences Holdings EBIT

Harmony Biosciences Holdings (HRMY) currently reports a EBIT of $240M as of June 2026. That compares with $240M in the prior-year period — up 3.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Harmony Biosciences Holdings's EBIT history and peer comparisons.

Harmony Biosciences Holdings's EBIT increased from $240M to $240M — a 3.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harmony Biosciences Holdings's EBIT of $240M is lower than the Healthcare sector average of $23B. That is roughly 98.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Harmony Biosciences Holdings reported $240M in EBIT as of June 2026. That compares with $240M in the prior-year period — up 3.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $240M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Harmony Biosciences Holdings, and consider following HRMY for alerts when major investors trade the stock.